Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Hancock Whitney Corp

Hancock Whitney Corp reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 47,907 shares of the company’s stock after selling 786 shares during the period. Hancock Whitney Corp owned approximately 0.15% of Medpace worth $19,731,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of MEDP. FORA Capital LLC purchased a new stake in shares of Medpace in the 1st quarter valued at approximately $2,222,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Medpace in the 1st quarter valued at approximately $5,179,000. Eagle Asset Management Inc. raised its position in Medpace by 155.0% in the fourth quarter. Eagle Asset Management Inc. now owns 226,435 shares of the company’s stock valued at $69,409,000 after purchasing an additional 137,632 shares during the period. Evoke Wealth LLC acquired a new position in Medpace during the fourth quarter worth $3,149,000. Finally, Norden Group LLC boosted its position in shares of Medpace by 488.0% during the first quarter. Norden Group LLC now owns 29,480 shares of the company’s stock worth $11,914,000 after buying an additional 24,466 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Down 0.9 %

NASDAQ MEDP opened at $365.70 on Friday. Medpace Holdings, Inc. has a 52 week low of $227.21 and a 52 week high of $459.77. The firm has a 50 day moving average of $378.15 and a two-hundred day moving average of $392.02. The stock has a market capitalization of $11.33 billion, a PE ratio of 37.28, a price-to-earnings-growth ratio of 1.74 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, July 22nd. The company reported $2.75 EPS for the quarter, beating the consensus estimate of $2.54 by $0.21. The firm had revenue of $528.10 million for the quarter, compared to analyst estimates of $528.41 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. Medpace’s revenue for the quarter was up 14.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.93 earnings per share. On average, equities research analysts expect that Medpace Holdings, Inc. will post 11.66 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on MEDP. Mizuho began coverage on Medpace in a report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price objective on the stock. StockNews.com lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Wednesday. TD Cowen lowered their price objective on shares of Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a research note on Wednesday, July 24th. Deutsche Bank Aktiengesellschaft cut their target price on shares of Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research note on Wednesday, July 24th. Finally, Truist Financial initiated coverage on shares of Medpace in a research report on Thursday, August 1st. They issued a “hold” rating and a $415.00 price target for the company. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $420.88.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.